Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Business Update & new Development Agreement signed

16 Oct 2008 07:00

RNS Number : 9551F
Oxford Advanced Surfaces Group PLC
16 October 2008
 



16 October 2008

Oxford Advanced Surfaces Group PLC (the 'Company')

Business Update and new Development Agreement signed

Oxford Advanced Surfaces Group plc announces the signing of its first development agreement in the biomedical sector. The group has been engaged by a European technology innovator working on novel medical devices in the field of gastroenterology. 

The Company is building a development portfolio across a broad range of applications and sectors, primarily through Joint Development Agreements ("JDAs") with leading players in a variety of markets but also advancing some in-house proofs of concept in selected applicationsEach of these projects, if they reach the market and are commercially successful, would represent a significant revenue and profit opportunity for both the customer and the Company.

 

With this new project we are now actively engaged in eleven  specific  development  programmes Eight of these are in sectors such as industrial materials, consumer goods, electronics and now biomedical. A further three are in-house development applications of the Onto™ technology for use in photovoltaic devices and solid state lighting. All of these programmes are in Stage 1 (Development of Materials). Whilst we expect a number of these projects to progress to Stage 2 (Process Development & Manufacturing Trials) some attrition will naturally occur. 

In addition we have a substantial pipeline of opportunities awaiting Initial Assessment or Proof of Concept ("PoC"). Many of these companies are global leaders in growth areas such as advanced materials, photovoltaics, solid state lighting and biomedical devices. Our immediate aim is to build and maintain a portfolio of 15-20 active projects at any point in time and to begin to advance one or two projects to Stage 2 in 2009. We are well on our way to achieving this goal.

The company is also involved in a number of collaborative or grant funded programmes. Currently, the Company is participating in a collaborative research and development project with the University of Manchester and the Centre for Process Innovation in the field of plastic electronics, sponsoring a Knowledge Transfer Partnership in photovoltaics with The University of Oxford, and has just been awarded a grant from the Carbon Trust to develop applications in solid state lighting.

Marcelo Bravo, Chief Executive of Oxford Advances Surfaces Group plc, said:

"I am delighted to announce our first engagement into the biomedical devices market. This market has great potential for us from general applications of the Onto technology through to specialised biological coatings and biofilm and infection control."

Contacts: 

Oxford Advanced Surfaces Group plc

Marcelo Bravo, Chief Executive

www.oxfordadvancedsurfaces.com

Tel: +44 (0)1865 845807

Novum Securities Limited - Broker

Henry Turcan

Michael Brennan

Tel: +44 (0)20 7562 4700

Zimmerman Adams International - Nominated Adviser

Ray Zimmerman/Jonathan Evans

Tel: +44 (0)20 7398 2900

Notes to Editors

Oxford Advanced Surfaces Group plc

Oxford Advanced Surfaces Group plc develops and commercialises advanced materials and technology solutions leveraging breakthrough surface modification technology.

Onto™ technology exploits highly reactive chemistry allowing the rapid and convenient modification of the surface properties of a wide range of materials with a high degree of control over processing parameters. Onto™ can be applied using standard commercial coating and curing techniques and is a versatile, effective, yet simple approach to deliver intelligent advanced materials. This delivers permanent, dramatic and highly valuable changes to surface functionality. 

The company is working with commercial partners to develop applications in the industrial, consumer, electronics, alternative energy and biomedical sectors. OASG was originally spun out of Oxford University in the United Kingdom and is now listed on London's Alternative Investment Market (AIM).

Website: www.oxfordsurfaces.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKESFFNPFFE
Date   Source Headline
24th Jan 20228:50 amRNSHolding(s) in Company
24th Jan 20227:00 amRNSHolding(s) in Company
20th Jan 202212:15 pmRNSResult of General Meeting
20th Jan 20227:00 amRNSResult of Open Offer - Correction
19th Jan 202211:30 amRNSResult of Open Offer
4th Jan 20221:30 pmRNSPosting of Circular and Notice of GM
29th Dec 20214:36 pmRNSPrice Monitoring Extension
24th Dec 20217:00 amRNSPlacing, Subscription and Open Offer
17th Dec 20215:00 pmRNSBusiness Update and Financing
22nd Oct 20217:00 amRNSAppointment of new Scientific Advisory Board
21st Oct 20218:00 amRNSDigitalGlassware® platform trial with Aurigene
28th Sep 20217:00 amRNSCollaboration
22nd Sep 20217:00 amRNSHalf Year Results
14th Sep 202110:30 amRNSNotice of Half Year Results
8th Sep 20211:30 pmRNSHolding(s) in Company
18th Aug 20217:00 amRNSAdvisory Board Appointment
5th Aug 20217:00 amRNSCollaboration with the University of Cambridge
12th Jul 20217:00 amRNSAppointment of Non-Executive Director
30th Jun 20213:34 pmRNSResult of AGM
22nd Jun 20217:00 amRNSChanges to 2021 AGM Arrangements
17th Jun 20217:00 amRNSCollaboration with the University of Leeds
8th Jun 20213:16 pmRNSPosting of ARA and Updated Notice of AGM
1st Jun 20217:00 amRNSFinal Results
24th May 20217:00 amRNSNotice of Results and Investor Presentation
6th May 20213:43 pmRNSHolding(s) in Company
7th Apr 20217:00 amRNSCollaboration with the University of Nottingham
11th Mar 20217:00 amRNSCo-distribution agreement with Elemental Machines
9th Mar 20217:00 amRNSDirectorate Change
20th Jan 20217:00 amRNSAgreement with Merck's Life Sciences business
19th Jan 20217:00 amRNSHolding(s) in Company
8th Jan 20212:00 pmRNSPrice Monitoring Extension
18th Dec 202010:30 amRNSGrant of PDMR Options
17th Dec 20207:00 amRNSMulti-year contract with Thieme Chemistry
26th Oct 202011:05 amRNSSecond Price Monitoring Extn
26th Oct 202011:00 amRNSPrice Monitoring Extension
21st Oct 20207:00 amRNSIssue of Shares and Total Voting Rights
19th Oct 20207:00 amRNSDirectorate Changes
16th Oct 20207:00 amRNSStrong adoption of ICSYNTH
2nd Oct 20202:05 pmRNSSecond Price Monitoring Extn
2nd Oct 20202:00 pmRNSPrice Monitoring Extension
1st Oct 20208:00 amRNSGrant of Options
29th Sep 20207:00 amRNSHolding(s) in Company
23rd Sep 20201:40 pmRNSHolding(s) in Company
22nd Sep 20204:29 pmRNSHolding(s) in Company
22nd Sep 20204:00 pmRNSHolding(s) in Company
22nd Sep 202010:32 amRNSHolding(s) in Company
15th Sep 20208:08 amRNSIssue of Shares and Total Voting Rights
10th Sep 20207:00 amRNSHalf-year Report
4th Sep 20208:26 amRNSHolding(s) in Company
3rd Sep 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.